---
layout: default
title: Head &amp; Neck Squamous Cell Carcinoma
---
<h2 class="unnumbered" id="head-neck-squamous-cell-carcinoma">
Head &
Neck Squamous Cell Carcinoma
</h2>
<h4 class="unnumbered" id="prognosis-by-stage">
Prognosis by Stage
</h4>
<p>
Stage 0 ---99%
</p>
<p>
Stage 1 --- 90-92%
</p>
<p>
Stage 2 --- 75-85%
</p>
<p>
Stage 3 --- 50%
</p>
<p>
Stage 4 --- 25-35%
</p>
<h4 class="unnumbered" id="who-gets-chemotherapy">
Who gets
chemotherapy
</h4>
<ul>
<li>
<p>
Nasopharyngeal CA: Stage III-IV, some Stage II
</p>
</li>
<li>
<p>
Unresectable H&N Ca
</p>
</li>
<li>
<p>
Laryngeal CA: induction cisplatin/5-FU for organ
preservation
</p>
</li>
<li>
<p>
Unknown Primary -- patients with N2,N3 disease
</p>
</li>
<li>
<p>
`<strong>Patients with positive margins or lymph nodes that have
ECS`</strong>
</p>
</li>
</ul>
<h4 class="unnumbered" id="who-gets-radiation-therapy-to-neck">
Who gets
radiation therapy to neck
</h4>
<ul>
<li>
<p>
Patients with N1 disease + extracapsular spread
</p>
</li>
<li>
<p>
Patients with N2-3 disease
</p>
</li>
</ul>
<h4 class="unnumbered" id="who-gets-a-neck-dissection">
Who gets a neck
dissection:
</h4>
<p>
Classic training is that if risk of spread to lymph nodes is
\>15-25%, should do neck dissection
</p>
<p>
`<strong>N0 disease in:`</strong>
</p>
<ul>
<li>
<p>
Oral Cavity - I - III
</p>
</li>
<li>
<p>
Oropharynx - II - IV
</p>
</li>
<li>
<p>
Hypopharynx/Larynx - II-IV, VI when appropriate
</p>
</li>
<li>
<p>
Subglottic - II-IV and VI
</p>
</li>
</ul>
<h3 class="unnumbered" id="oral-cavity-ca">
Oral Cavity CA
</h3>
<p>
`<strong>Management`</strong>
</p>
<ul>
<li>
<p>
Excision w/ reconstruction. Tumors \<2cm can be approached
transorally
</p>
<ul>
<li>
<p>
Mandible: Abutting periosteum - can get away with a marginal
mandibulectomy. Invasion of mandible - need a segmental
resection
</p>
</li>
<li>
<p>
N0 necks: elective ipsi/bilateral (b/l if midline) level I-III
(Can avoid neck dissection in T1/2 N0 lower lips).
</p>
</li>
<li>
<p>
N1+ neck: selective I-III ND.
</p>
</li>
<li>
<p>
RT if positive nodes. Chemotherapy if adverse features (positive
margins, ECS on LNs)
</p>
</li>
</ul>
<h3 class="unnumbered" id="oropharyngeal-ca">
Oropharyngeal CA
</h3>
<p>
`<strong>Sites`</strong>:
</p>
<ul>
<li>
<p>
Tonsil: MC, aggressive, high risk of occult LN spread
</p>
</li>
<li>
<p>
Base of tongue: also aggressive w/ high rates of LN
spread
</p>
</li>
<li>
<p>
Posterior pharyngeal wall and soft palate = less
aggressive
</p>
</li>
</ul>
<p>
T1-T2: excision vs primary XRT.
</p>
<p>
N0: XRT or elective unilateral or bilateral ND levels II-IV.
</p>
<p>
N1: XRT selective ND II-IV.
</p>
<p>
N2-3: Chemorads + selective ND
</p>
<p>
T3-T4: typically treated with radiation
</p>
<h3 class="unnumbered" id="laryngeal-ca">
Laryngeal CA
</h3>
<h4 class="unnumbered" id="premalignant-glottic-lesions">
Premalignant
Glottic Lesions
</h4>
<ul>
<li>
<p>
Hyperplasia/Hyperkeratosis - `<u>not a risk for
malignancy`</u>
</p>
</li>
<li>
<p>
Dysplasia
</p>
<ul>
<li>
<p>
Severe dysplasia/Carcinoma in situ- risk is 15-25%
</p>
</li>
<li>
<p>
CIS has features of malignancy but `<u>not invaded beyond basement
membrane`</u>
</p>
</li>
<li>
<p>
Excisions
</p>
<ul>
<li>
<p>
Microflap excision: Dissects superficial lamina propria and
`<u>spares vocal ligament`</u>
</p>
</li>
</ul>
<h4 class="unnumbered" id="hypopharyngeal-ca">
Hypopharyngeal CA
</h4>
<ul>
<li>
<p>
Hypopharynx: Level of hyoid bone to the cricopharyngeus behind
the larynx
</p>
</li>
<li>
<p>
`<strong>Piriform sinus`</strong> is most common location
</p>
<ul>
<li>
<p>
Post-cricoid region: think plummer-vinson syndrome
</p>
</li>
<li>
<p>
Most are diagnosed at advanced stage
</p>
<ul>
<li>
<p>
Hypopharynx may have skip lesions
</p>
</li>
<li>
<p>
Management
</p>
<ul>
<li>
<p>
T1, some T2, N0 - partial laryngopharygectomy
</p>
</li>
<li>
<p>
Always do Level II-IV neck dissection even in N0 disease
</p>
</li>
<li>
<p>
Techniques
</p>
<ul>
<li>
<p>
`<strong>Partial laryngopharyngectomy`</strong>
</p>
<ul>
<li>
<p>
For T1 (some T2) piriform sinus cancer
</p>
</li>
<li>
<p>
Must involve `<strong>medial wall`</strong> and be `<strong>1.5cm
away from apex`</strong>
</p>
</li>
<li>
<p>
`<strong>Lateral + suprahyoid pharyngectomy`</strong>
</p>
<ul>
<li>
<p>
For `<u>posterior`</u> cricopharyngeal wall CA
</p>
</li>
<li>
<p>
Total laryngectomy with partial pharyngectomy
</p>
<ul>
<li>
<p>
For advance CA and `<u>post-cricoid`</u> CA
</p>
</li>
<li>
<p>
For these, need reconstruction with tension-free
closure.
</p>
</li>
</ul>
<h4 class="unnumbered" id="laryngeal">
LARYNGEAL
</h4>
<ul>
<li>
<p>
Sites
</p>
<ul>
<li>
<p>
`<strong>Supraglottis`</strong>: High rate of note metastasis.
Typically to bilateral II-IV
</p>
</li>
<li>
<p>
`<strong>Glottis`</strong>: Most common site in larynx
</p>
<ul>
<li>
<p>
Less spread due to barriers (vocal ligament, thyroglottic
ligament)
</p>
</li>
<li>
<p>
Anterior commissure - `<u>no inner perichondrium`</u> allows for
anterior spread to thyroid cartilage
</p>
</li>
<li>
<p>
`<strong>Subglottic`</strong>: Rare, poor prognosis
</p>
</li>
<li>
<p>
Treatments
</p>
<ul>
<li>
<p>
Laser surgery
</p>
<ul>
<li>
<p>
Ideal for T1 glottic or supraglottic SCCA. Risk of
scarring
</p>
</li>
<li>
<p>
`<strong>Anterior commissure involvement`</strong> - associated
with high recurrence rates
</p>
</li>
<li>
<p>
Surgery
</p>
<ul>
<li>
<p>
Cordectomy---Indication: T1 glottic cancer restricted to `<u>middle
1/3 of vocal fold`</u>
</p>
</li>
<li>
<p>
Conservative/Function Laryngectomies:
</p>
<ul>
<li>
<p>
Contraindication to partial laryngectomies is poor pulmonary
function
</p>
</li>
<li>
<p>
Vertical partial laryngectomy (Hemi laryngectomy)
</p>
<ul>
<li>
<p>
high risk of aspiration, must have really go pulmonary
<ul>
<li>
<p>
Can decrease risk by `<strong>turning to operated side`</strong>
and performing a `<strong>chin tuck`</strong>
</p>
</li>
<li>
<p>
T1/T2 glottic CA that doesn't extend beyond 1/3 of opposite cord
or involve posterior commissure
</p>
</li>
<li>
<p>
Supraglottic partial laryngectomy (Horizontal
Hemi-laryngectomy)
</p>
<ul>
<li>
<p>
For `<strong>T1/T2 `<em>supraglottic`</em> tumors`</strong>
</p>
</li>
<li>
<p>
preservation of both true vocal cords and arytenoids - preserves
voice
</p>
</li>
<li>
<p>
Disadvantage: needs initial trach, increased aspiration risk as
SLN is taken
</p>
</li>
<li>
<p>
Supracricoid partial laryngectomy
</p>
<ul>
<li>
<p>
Must preserve `<u>one functional cricoarytenoid unit`</u>
(arytenoid, cricoid and hyoid and associated musculature, plus the
superior and recurrent laryngeal nerve)
</p>
</li>
<li>
<p>
Resects supraglottis plus vocal fold, thyroid cartilage, and
paraglottic space
</p>
</li>
<li>
<p>
`<strong>Select T3/T3 supraglottic/glottic CA`</strong> - must not
have `<strong>arytenoid fixation`</strong>
</p>
</li>
<li>
<p>
Open partial laryngectomy: Resects anterior commissure for select
cases
</p>
</li>
<li>
<p>
`<strong>Contraindications`</strong>:
</p>
<ul>
<li>
<p>
Cartilage invasion, `<strong>VF fixation`</strong>, interarytenoid
involvement, tongue base involvement, poor performance status
</p>
</li>
<li>
<p>
Total laryngectomy:
</p>
<ul>
<li>
<p>
With addition of pharyngeal structures such as piriform sinus or
laryngeal pharyngeal wall if needed
</p>
</li>
<li>
<p>
Radiation: Used for T1/T2 lesions
</p>
</li>
<li>
<p>
Neck Dissections
</p>
<ul>
<li>
<p>
Hypopharyngeal: Yes starting at T1 (With T2 or N1, should also do
Level VI)
</p>
</li>
<li>
<p>
Supraglottic: yes for T1 N0
</p>
</li>
</ul>
<p>
`<a href="../index.html">Back to homepage`</a>
</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
